CureVac N.V. (CVAC) Stock

About CureVac N.V.

CureVac N.V. is a biopharmaceutical company currently in the clinical stage, specializing in creating innovative medical treatments leveraging messenger ribonucleic acid (mRNA) technology. Its portfolio encompasses various mRNA-based prophylactic vaccines. Among these is CV2CoV, an mRNA vaccine candidate addressing SARS-CoV-2, presently in Phase 1 clinical investigation. Another key candidate, CV7202, an mRNA prophylactic targeting the rabies virus glycoprotein, has successfully completed its Phase 1 clinical evaluation. Additionally, CVSQIV, aimed at influenza, is also undergoing Phase 1 clinical trials. Further vaccine development efforts are directed towards lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and a universal influenza solution. Beyond its vaccine initiatives, CureVac is also engaged in developing RNA-based immunotherapies for cancer. For instance, CV8102, an immunotherapy, is currently undergoing Phase 1 trials for the treatment of cutaneous melanoma, adenoidcystic carcinoma, and squamous cell carcinoma affecting the skin, head, and neck. The company was established in 2000 and operates from its main office in Tübingen, Germany.

CureVac N.V. is headquartered in DE.

CureVac N.V. (CVAC) stock trades at $4.66 with a market capitalization of $1.05B. The stock is valued at a price-to-earnings (P/E) ratio of 5.69, price-to-book of 1.05, price-to-sales of 16.33. Over the past 52 weeks the stock has ranged between $2.48 and $5.72, and currently trades 18.5% below its 52-week high.

On profitability, CureVac N.V. generates a return on equity (ROE) of 23.04% — well above the market average, a sign of a high-quality business, return on capital employed of 21.47%, an operating margin of 344.28%, a net profit margin of 287.15%.

Official website: www.curevac.com